1. Home
  2. BAFN vs CTSO Comparison

BAFN vs CTSO Comparison

Compare BAFN & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$6.70

Market Cap

40.6M

Sector

Finance

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.67

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAFN
CTSO
Founded
1999
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.6M
45.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BAFN
CTSO
Price
$6.70
$0.67
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
14.0K
79.8K
Earning Date
01-29-2026
03-11-2026
Dividend Yield
2.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$39,595,000.00
$36,979,520.00
Revenue This Year
N/A
$7.95
Revenue Next Year
N/A
$8.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.89
52 Week Low
$5.72
$0.60
52 Week High
$19.75
$1.61

Technical Indicators

Market Signals
Indicator
BAFN
CTSO
Relative Strength Index (RSI) 49.67 48.34
Support Level $6.32 $0.63
Resistance Level $7.10 $0.73
Average True Range (ATR) 0.39 0.05
MACD 0.09 -0.00
Stochastic Oscillator 92.02 38.09

Price Performance

Historical Comparison
BAFN
CTSO

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: